Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

To gain insights into the characteristics of clinical resistance to lenalidomide, we evaluated the outcomes of 147 consecutive patients with multiple myeloma (MM) homogeneously treated with immunomodulatory imide drugs (IMiDs) pomalidomide and dexamethasone (Pd) for relapsed and/or refractory MM (me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Kastritis, Efstathios, Roussou, Maria, Gavriatopoulou, Maria, Kanellias, Nikolaos, Migkou, Magdalini, Eleutherakis-Papaiakovou, Evangelos, Ziogas, Dimitrios C., Fotiou, Despina, Ntanasis-Stathopoulos, Ioannis, Dialoupi, Ioanna, Giannouli, Stavroula, Tsirigotis, Panagiotis, Delimpasi, Sossana, Mparmparousi, Despina, Spyropoulou-Vlachou, Mairylin, Xirokosta, Aikaterini, Terpos, Evangelos, Dimopoulos, Meletios A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6963239/
https://ncbi.nlm.nih.gov/pubmed/31821457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000539
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados